News related to Metformin Extended-Release and/or conditions it is approved for
Lasting Benefit Seen for Lifestyle Changes, Metformin in Diabetes (CME/CE)
Source: MedPage Today Endocrinology [2009.10.28]
Early use of lifestyle modifications or, to a lesser extent, metformin treatment, in people at risk for type 2 diabetes appeared to pay off for 10 years, researchers said.
Metformin May Lower Diabetics' Odds for Pancreatic Cancer
Source: MedicineNet metformin Specialty [2009.08.03]
Title: Metformin May Lower Diabetics' Odds for Pancreatic Cancer
Category: Health News
Created: 8/3/2009 7:00:00 AM
Last Editorial Review: 8/3/2009
Sitagliptin Approved As Add-on To Insulin
Source: Diabetes News From Medical News Today [2009.11.22]
Sitagliptin (known as Januvia) has been approved by the European Commission as an add-on to insulin (with or without metformin) for people with Type 2 diabetes who cannot control their condition effectively with a combination of diet, physical activity and insulin. Sitagliptin is a once-daily DPP-4 inhibitor that works by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
|
